Sept. 26, 2022 |
Sept. 23, 2022 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
8,200
+5.3%
1.23
10,086
USD
|
8,200
+5.3%
|
1.23
|
10,086
USD
|
|
Sept. 26, 2022 |
Sept. 22, 2022 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
37,037
+31.5%
1.34
49,630
USD
|
37,037
+31.5%
|
1.34
|
49,630
USD
|
|
June 24, 2022 |
June 22, 2022 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
33,784
+40.3%
1.50
50,676
USD
|
33,784
+40.3%
|
1.50
|
50,676
USD
|
|
March 21, 2022 |
March 17, 2022 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
16,677
+85.5%
3.08
51,365
USD
|
16,677
+85.5%
|
3.08
|
51,365
USD
|
|
June 25, 2021 |
June 23, 2021 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
30,000
-21.2%
10.65
319,500
USD
|
30,000
-21.2%
|
10.65
|
319,500
USD
|
|
June 23, 2021 |
June 21, 2021 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
15,000
-11.9%
10.77
161,550
USD
|
15,000
-11.9%
|
10.77
|
161,550
USD
|
|
June 21, 2021 |
June 18, 2021 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
10,000
-8.2%
11.00
110,000
USD
|
10,000
-8.2%
|
11.00
|
110,000
USD
|
|
June 21, 2021 |
June 17, 2021 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
10,000
-8.2%
10.44
104,400
USD
|
10,000
-8.2%
|
10.44
|
104,400
USD
|
|
June 16, 2021 |
June 15, 2021 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
2,858
-2.5%
11.20
32,010
USD
|
2,858
-2.5%
|
11.20
|
32,010
USD
|
|
June 15, 2021 |
June 11, 2021 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
30,000
-21.2%
11.52
345,600
USD
|
30,000
-21.2%
|
11.52
|
345,600
USD
|
|
May 19, 2021 |
May 17, 2021 |
S
Sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
20,000
-0.5%
9.38
187,600
USD
|
20,000
-0.5%
|
9.38
|
187,600
USD
|
|
May 18, 2021 |
May 14, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,673
-0.2%
9.17
88,701
USD
|
9,673
-0.2%
|
9.17
|
88,701
USD
|
|
May 14, 2021 |
May 13, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,675
-0.5%
8.96
86,688
USD
|
9,675
-0.5%
|
8.96
|
86,688
USD
|
|
May 14, 2021 |
May 13, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,673
-0.2%
9.15
88,508
USD
|
9,673
-0.2%
|
9.15
|
88,508
USD
|
|
May 14, 2021 |
May 12, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,676
-0.2%
8.72
84,375
USD
|
9,676
-0.2%
|
8.72
|
84,375
USD
|
|
May 11, 2021 |
May 10, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,746
-0.5%
8.25
80,405
USD
|
9,746
-0.5%
|
8.25
|
80,405
USD
|
|
May 11, 2021 |
May 7, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,742
-0.5%
8.57
83,489
USD
|
9,742
-0.5%
|
8.57
|
83,489
USD
|
|
April 21, 2021 |
April 19, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,676
-0.2%
8.69
84,084
USD
|
9,676
-0.2%
|
8.69
|
84,084
USD
|
|
April 19, 2021 |
April 16, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,675
-0.2%
8.84
85,527
USD
|
9,675
-0.2%
|
8.84
|
85,527
USD
|
|
April 19, 2021 |
April 15, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,676
-0.2%
8.76
84,762
USD
|
9,676
-0.2%
|
8.76
|
84,762
USD
|
|
March 22, 2021 |
March 18, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,665
-0.2%
11.08
107,088
USD
|
9,665
-0.2%
|
11.08
|
107,088
USD
|
|
March 18, 2021 |
March 17, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,665
-0.2%
10.92
105,542
USD
|
9,665
-0.2%
|
10.92
|
105,542
USD
|
|
March 18, 2021 |
March 16, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,661
-0.2%
11.97
115,642
USD
|
9,661
-0.2%
|
11.97
|
115,642
USD
|
|
March 16, 2021 |
March 12, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,712
-0.5%
11.36
110,328
USD
|
9,712
-0.5%
|
11.36
|
110,328
USD
|
|
March 12, 2021 |
March 11, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,711
-0.5%
11.38
110,511
USD
|
9,711
-0.5%
|
11.38
|
110,511
USD
|
|
March 12, 2021 |
March 10, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,710
-0.5%
11.79
114,481
USD
|
9,710
-0.5%
|
11.79
|
114,481
USD
|
|
Feb. 24, 2021 |
Feb. 22, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,660
-0.2%
12.04
116,306
USD
|
9,660
-0.2%
|
12.04
|
116,306
USD
|
|
Feb. 22, 2021 |
Feb. 19, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,663
-0.2%
11.55
111,608
USD
|
9,663
-0.2%
|
11.55
|
111,608
USD
|
|
Feb. 22, 2021 |
Feb. 18, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
6,871
-0.2%
12.20
83,826
USD
|
6,871
-0.2%
|
12.20
|
83,826
USD
|
|
Feb. 22, 2021 |
Feb. 18, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,705
-0.5%
12.23
118,692
USD
|
9,705
-0.5%
|
12.23
|
118,692
USD
|
|
Feb. 18, 2021 |
Feb. 17, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,705
-0.5%
12.28
119,177
USD
|
9,705
-0.5%
|
12.28
|
119,177
USD
|
|
Feb. 18, 2021 |
Feb. 16, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,697
-0.5%
13.30
128,970
USD
|
9,697
-0.5%
|
13.30
|
128,970
USD
|
|
Feb. 2, 2021 |
Jan. 29, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
6,444
-0.2%
12.25
78,939
USD
|
6,444
-0.2%
|
12.25
|
78,939
USD
|
|
Jan. 29, 2021 |
Jan. 28, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
6,444
-0.2%
11.97
77,135
USD
|
6,444
-0.2%
|
11.97
|
77,135
USD
|
|
Jan. 29, 2021 |
Jan. 27, 2021 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
7,048
-0.2%
11.68
82,321
USD
|
7,048
-0.2%
|
11.68
|
82,321
USD
|
|
Jan. 28, 2021 |
Jan. 26, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,697
-0.5%
13.37
129,649
USD
|
9,697
-0.5%
|
13.37
|
129,649
USD
|
|
Jan. 26, 2021 |
Jan. 25, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,695
-0.5%
13.74
133,209
USD
|
9,695
-0.5%
|
13.74
|
133,209
USD
|
|
Jan. 26, 2021 |
Jan. 22, 2021 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
10,218
-0.6%
13.53
138,250
USD
|
10,218
-0.6%
|
13.53
|
138,250
USD
|
|
Jan. 25, 2021 |
Jan. 21, 2021 |
PS
Planned sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
10,000
-8.4%
16.49
164,900
USD
|
10,000
-8.4%
|
16.49
|
164,900
USD
|
|
Dec. 20, 2019 |
Dec. 19, 2019 |
B
Purchase
|
Heery Christopher
Chief Medical Officer
Officer
|
2,235
+894.0%
12.08
26,999
USD
|
2,235
+894.0%
|
12.08
|
26,999
USD
|
|
Dec. 20, 2019 |
Dec. 19, 2019 |
B
Purchase
|
Heery Christopher
Chief Medical Officer
Officer
|
250
+inf%
12.09
3,023
USD
|
250
+inf%
|
12.09
|
3,023
USD
|
|
April 4, 2019 |
April 3, 2019 |
B
Purchase
|
YAO TONY DUNG LING
|
6,487
+4.3%
15.42
100,030
USD
|
6,487
+4.3%
|
15.42
|
100,030
USD
|
|
April 3, 2019 |
April 1, 2019 |
B
Purchase
|
FMR LLC
See Remark 1
|
50,000
+1.4%
16.00
800,000
USD
|
50,000
+1.4%
|
16.00
|
800,000
USD
|
|
April 1, 2019 |
April 1, 2019 |
B
Purchase
|
venBio Global Strategic Fund, L.P.
Major owner
|
50,000
+inf%
16.00
800,000
USD
|
50,000
+inf%
|
16.00
|
800,000
USD
|
|